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Abstract
Background: The occurrence of cervical intraepithelial neoplasia (CIN) is associated with changes in health-related
quality of life, including psychological factors, such as fear and shame, and changes in sexuality and sexual satisfaction,
such as decreased sexual desire and frequency of sexual intercourse. Personal relationships are the most affected
because CIN is sexually transmitted and many women tend to blame their partner for disease transmission. The
aim of this study was to evaluate the psychometric properties of the FACIT-CD questionnaire in Brazilian women
diagnosed with CIN.
Methods: The properties of the FACIT-CD questionnaire were tested on a sample of 439 women seen at the
Department of Prevention of Barretos Cancer Hospital, including 329 patients who were diagnosed with CIN and
110 women who were not diagnosed with the disease. The analysed parameters included internal consistency
(Cronbach’s alpha), reproducibility (intraclass correlation coefficient), structural validity, convergent validity (correlation
with the SF-12 and EORTC QLQ-CX24 questionnaires), discriminant validity (according to disease status, and self-rating
of health), sensitivity, and responsiveness.
Results: The Cronbach alpha values of the FACIT-CD scales were higher than 0.70 with the exception of the relationship
scale (0.66). The FACIT-CD reproducibility was satisfactory, with variation in the intraclass correlation coefficients ranging
between 0.50 and 0.83, although the 95% confidence interval (CI) was lower than 0.40 (0.33–0.64) on the treatment
satisfaction scale. Regarding structural validity, only one item on the physical well-being scale was not kept in the
original domain. The expected correlations between the FACIT-CD and SF-12 were not confirmed, whereas the
correlations between the FACIT-CD and EORTC QLQ-CX24 were confirmed. The questionnaire was able to discriminate
the groups according to disease status and self-rating of health. The sensitivity was low for the relationship scale and
moderate for the other scales. The responsiveness of the FACIT-CD questionnaire varied between the groups that
denominate the self-perception of health as no change, improvement or worsening.
Conclusion: Our results are encouraging and indicate that the FACIT-CD questionnaire is a promising tool for the
analysis of the quality of life of women with CIN.
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Background
Human papillomavirus (HPV) infection is the most preva-
lent sexually transmitted disease worldwide [1]. Approxi-
mately 440 million people are estimated to have genital
HPV infections worldwide [2], and approximately 10% of
women will carry HPV at some point in their life [3].
Approximately 40 types of HPV can invade the mucous
membranes of the upper aerodigestive tract and anoge-
nital region of humans; these HPV types are classified as
low and high risk according to their carcinogenic potential
[4]. Low-grade intraepithelial lesions spontaneously re-
gress in 60% of cases, and only 10% of cases progress to
high-grade lesions. Even cervical carcinoma in situ (CIN
3) may undergo spontaneous regression to normality in
one-third of women [4]. The period from HPV infection
to the onset of invasive cervical cancer is estimated to ex-
tend 10 to 20 years, which makes this disease preventable
using well-structured screening strategies [5].
The occurrence of cervical intraepithelial neoplasia is
associated with changes in health-related quality of life
(HRQoL), including psychological factors, such as fear
and shame, and changes in sexuality and sexual satisfac-
tion, such as decreased sexual desire and decreased fre-
quency of sexual intercourse [6–8]. Such problems tend
to sustain for a period of time after the treatment [9].
Anxiety, distress, concern with fertility, changes in fam-
ily dynamics and work-related changes are also negative
effects of CIN diagnosis and treatment [10–13]. Because
this disease is sexually transmitted, many women tend to
blame their partner for transmission [13, 14].
Despite the availability of instruments to objectively
assess HRQoL, few instruments have investigated the
impact of HPV infection in the female genital tract. The
number of studies on aspects related to HRQoL in
women diagnosed with cervical cancer has significantly
increased. This increased interest can be justified by the
magnitude of the disease, which predominantly affects
young women who will live the rest of their lives with
the consequences of the disease and treatment [15–18].
However, little is known about the impact of diagnosis
and treatment on HRQoL in women diagnosed with pre-
cursor lesions of cervical cancer.
In 2010, Rao et al. [6] developed a tool that was desig-
nated the Functional Assessment of Chronic Illness
Therapy – Cervical Dysplasia (FACIT-CD) to assess the
functional, physical, and psychological characteristics of
women with CIN. The questionnaire has recently been
translated and adapted to Brazilian Portuguese.
The FACIT system questionnaires are easy to apply
(self-applied or using interviews), require little time to
complete, have adequate validity and sensitivity to detect
changes, and are designed to reach a population with a
level of education corresponding to the fourth year of
primary school (9–10-year-old age group) [19].
The aim of this study was to evaluate the psychometric
properties of the FACIT-CD questionnaire in Brazilian
women diagnosed with CIN.
Methods
This methodological longitudinal study was conducted
in the Department of Prevention and Oncological Gy-
naecology of the Barretos Cancer Hospital, Barretos,
state of São Paulo, Brazil. A total of 439 women were eli-
gible, including 329 women with a histopathological
diagnosis of CIN (low or high grade) without treatment
and 110 women not diagnosed with the disease. The
participants attended the Department of Prevention for
screening via a cervical cytology examination (Papanico-
laou test). Illiterate women and women known to have
psychological or psychiatric disorders that could hinder
the understanding of the questionnaire and the informed
consent form were excluded.
After formal agreement to participate in the study, the
participants answered the questionnaires, which were
applied using interviews by a single interviewer. Sociode-
mographic and clinical data were initially collected.
Then, the FACIT-CD, EORTC QLQ-CX24, and SF-12
(version 2) questionnaires were applied; this step was
considered the first stage of the study.
Among the 329 women diagnosed with CIN, the first
112 were selected to answer the FACIT-CD questionnaire
a second time to assess the reproducibility of the instru-
ment. Interviews were conducted in a second consultation
30 days after the first interview to inform the test results.
Of the 112 women selected, 87 (77.7%) returned on the
expected date and answered the questionnaire.
The responsiveness and sensitivity of the FACIT-CD
questionnaire were evaluated in 228 participants with a
medical indication for surgical treatment using the loop
electrosurgical excisional procedure (LEEP). Of this total,
179 (78.5%) returned after treatment during the stipulated
period (4–6 months) and answered the FACIT-CD ques-
tionnaire a second time and the first question of the SF-12
questionnaire (“In general, would you say your health is:”).
The responses obtained to this question at baseline and
after treatment allowed the creation of groups and the
classification of women as having improved health, wors-
ened health, or no change in health. Among the other
participants who underwent LEEP (49 women), 7 pre-
sented with invasive carcinoma and were forwarded to the
Department of Oncological Gynaecology, 12 women
returned outside the period stipulated for re-application of
the questionnaire, and the remaining participants did not
return on the previously scheduled date.
FACIT-CD questionnaire
The FACIT-CD instrument in Brazilian Portuguese is a
specific instrument to assess the HRQoL of women with
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CIN and comprises 37 questions divided into five scales
to assess aspects related to physical well-being (9 ques-
tions), treatment satisfaction (4 questions), general per-
ception (7 questions), emotional well-being (11 questions),
and relationships (6 questions). The scores were calculated
using the specific guidelines provided by the FACIT [20].
The responses were based on experiences from the last 7
days. The answer scale is Likert, with scores ranging
between 0 and 4 (a little bit to very much). A score was
assigned to each scale, and the scores were summed to
obtain a single value. The total score of the question-
naire ranged from 0 to 136. A higher score indicated a
better HRQoL.
EORTC QLQ-CX24 questionnaire
The EORTC QLQ-CX24 questionnaire was developed and
validated cross-culturally by the European Organization
for Research and Treatment of Cancer and was used for
the assessment of HRQoL in patients with cervical cancer
[21]. This instrument consists of 24 questions divided into
three scales of multiple items and six scales of single items,
including 11 questions on symptoms (questions 31 to 37,
39, and 41 to 43), 3 questions on body image (questions 45
to 47), 4 questions on sexual/vaginal function (questions
50 to 53), 1 question on lymphedema (question 38), 1
question on peripheral neuropathy (question 40), 1 ques-
tion on menopause symptoms (question 44), 1 question on
sexual worry (question 48), 1 question on sexual activity
(question 49), and 1 question on sexual enjoyment (ques-
tion 54). The scores were calculated separately for each
scale of the multiple and single items to allow the evalu-
ation of sexuality using the questions on sexual/vaginal
function, sexual activity, and sexual enjoyment [21].
SF-12 questionnaire
The SF-12 questionnaire is a generic instrument for the
assessment of HRQoL. This questionnaire is considered
a smaller version of the Medical Outcomes Study 36 –
Item Short-Form Health Survey (SF-36). The main goal
of developing an instrument with a reduced number of
items was to provide a questionnaire that could be an-
swered quickly and easily, which is a good option for
population-based studies and health screening [22]. The
questionnaire consists of 12 questions derived from the
SF-36 questionnaire. In Brazil, the SF-36 questionnaire
was translated into Brazilian Portuguese and validated
by Ciconelli et al. in 1999 [23]. The scores were calcu-
lated using specific software provided by the Medical
Outcomes Health Survey.
Analysis of psychometric properties
The classical psychometric properties of the FACIT-CD
questionnaire were tested by assessing the internal
consistency, reproducibility, structural validity, convergent
and divergent validity, known-group validity, sensitivity,
and responsiveness.
Cronbach’s alpha coefficient was used to test the in-
ternal consistency of the instrument, with values equal
to or higher than 0.70 considered appropriate [24]. The
reproducibility of the FACIT-CD was evaluated by com-
paring the scores obtained in the questionnaire during
the first and second interviews. For this purpose, the
intraclass correlation coefficient (ICC) was used. Struc-
tural validity was assessed using a confirmatory factor
analysis. The oblique rotation method was used for prin-
cipal component analysis, and a five-factor solution was
forced, as presented in the original questionnaire. For
the analysis of convergent and divergent validity, the
scores generated by the FACIT-CD questionnaire were
correlated with the scores generated by the SF-12 ques-
tionnaire and the scores of the scales that assessed se-
xuality in the EORTC QLQ-CX24 questionnaire. The
Spearman correlation coefficient was used to calculate
the correlations, with values higher than 0.40 considered
appropriate [25]. The assumptions of correlations be-
tween the FACIT-CD, SF-12, and EORTC QLQ-CX24
scales were established a priori.
To assess the known-group validity, women without
the disease were compared with women diagnosed with
CIN using the Mann-Whitney test. These two groups
were also assessed based on the answers to the first
question of the SF-12 (“In general, would you say your
health is:”). The responses were classified as excellent/
very good, good, and poor/very poor and were compared
using the Kruskal-Wallis test.
Sensitivity was evaluated by calculating the magnitude
of the effect using the Cohen’s D, standardized response
mean (SRM), and relative efficiency tests [26]. The tests
were applied to the groups before and after treatment.
Responsiveness was analysed using hypotheses estab-
lished a priori. For this purpose, the study groups were
compared before and after treatment (LEEP). The refer-
ence statistical method most commonly used to measure
the magnitude of changes in HRQoL scores is the as-
sessment of the effect size (ES) and the SRM [27, 28],
which provide useful data concerning significant changes
in clinical practice [29]. The ES and SRM are defined
using Cohen’s criteria, in which values up to 0.20 indi-
cate low responsiveness, values up to 0.50 indicate mod-
erate responsiveness, and values higher than 0.80
indicate high responsiveness [26, 30]. The level of sig-
nificance was 5% in all statistical tests.
Ethical considerations
This study was approved by the Research Ethics Commit-
tee of the Barretos Cancer Hospital under CAAE No.
36619714.9.0000.5432, and all the women who agreed to
participate in the study signed an informed consent form.
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Results
The characteristics of the study sample are shown in
Table 1. The mean age of the women was 35.2 ± 10.1 years;
most participants had a low education level and were
Caucasian, married, and worked from home. The most
common cytological result was a high-grade squamous
intraepithelial lesion (ASC-H), and the most common
histopathological result was CIN 2/3.
Table 2 shows the descriptive statistical analysis con-
ducted using the scores obtained in each of the scales and
the corresponding Cronbach’s alpha coefficients and intra-
class correlation coefficients (ICC). Only the relationship
scale presented a Cronbach’s alpha coefficient smaller than
0.70, with a value of 0.66. The coefficients that evaluated
the reproducibility of the FACIT-CD questionnaire scales
ranged between 0.50 and 0.83; however, the lower limit of
the 95% CI was smaller than 0.40 only on the treatment
satisfaction scale.
In the known-group validity analysis, the comparison
between the groups of women with and without a diag-
nosis of the disease indicated significant differences in
the average scores on all FACIT-CD questionnaire
scales. Considering the health status rating by each par-
ticipant, the group of women who rated their health as
excellent/very good had significantly higher scores on all
scales compared with the groups that rated their health
as good or fair/poor (Table 3).
Regarding the structural validity of the FACIT-CD ques-
tionnaire (Table 4), the factor components were similar to
those of the original questionnaire. The only exception was
question GP5 ("I am bothered by side effects of treatment");
although this question belonged to the physical well-being
domain in the original questionnaire, it presented higher
factor loading in the emotional well-being domain.
The convergent analysis results of the FACIT-CD
questionnaire are shown in Table 5. The correlation
Table 1 Sociodemographic and clinical characteristics of the study sample
Variable Description Diagnosed with CIN Not diagnosed with CIN
N = 329 N = 110
Age (Mean age) 35.2 48.5
Years of study ≤ 8 years 175 (53.2%) 58 (52.7%)
> 8 years 154 (46.8%) 52 (47.3%)
Race Caucasian 239 (72.6%) 82 (74.6%)
Mixed 46 (14%) 13 (11.8%)
Black 42 (12.8%) 11 (10%)
Asian 2 (0.6%) 4 (3.6%)
Marital status Married/cohabitating 175 (53.2%) 77 (70%)
Single 103 (31.3%) 13 (11.8%)
Separated/Divorced 37 (11.2%) 14 (12.7%)
Widow 14 (4.3%) 6 (5.5%)
Occupation Works from home 87 (26.4%) 4 (31%)
Housewife 43 (13.1%) 16 (14.4%)
Rural worker 17 (5.2%) 2 (1.8%)
Saleswoman 17 (5.2%) 2 (1.8%)
Other 165 (50.1%) 56 (51%)
Cytological result NILM 12 (3.6%) 106 (96.4%)
ASCUS 23 (7%) 4 (3.6%)
ASCH 148 (45%) –
AGC 5 (1.5%) –
LSIL 54 (16.4%) –
HSIL 87 (26.5%) –
Histological results CIN I 133 (40.4%) –
CIN II/III 195 (59.3%) –
Invasive cancer 1 (0.3%) –
NILM Negative for intraepithelial lesion or malignancy, ASCUS Atypical squamous cells of undetermined significance, ASCH Atypical squamous cells – cannot
exclude HSIL, AGC Atypical Glandular Cells not otherwise specified, LSIL Low grade squamous intraepithelial lesion, HSIL High grade squamous intraepithelial
lesion, CIN cervical intraepithelial neoplasia
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between the FACIT-CD and SF-12 scales was weak (rs <
0.40). The correlation between the FACIT-CD and
EORTC QLQ-CX24 scales was moderate (r = 0.40–0.60),
which confirmed previously established assumptions.
Table 6 shows the sensitivity of the questionnaire to
detect changes. The sensitivity of the relationship scale
was considered low (ES = 0.17, SEM = 0.19). The sen-
sitivities of the other scales that composed the FACIT-
CD questionnaire were moderate (ES = 0.31–0.43; SEM
= 0.29–0.52).
The results of the responsiveness analysis indicated in-
crease in the scores of the scales among women who re-
ported improved health (4/5 scales) (Table 7). The
magnitude of the change was moderate (ES = 0.27–0.58;
SEM = 0.30–0.71). In this same group, the only scale in
which the scores worsened after treatment was general
perceptions (18.5–17.4; p = 0.001). The same scale indi-
cated worsened HRQoL scores when the sensitivity of
the FACIT-CD questionnaire was evaluated.
Among women without changes in health between the
assessments, the average scores remained unchanged
(8.6–8.8; p = 0.021) and had low responsiveness (ES =
0.009; SEM = 0.10) only in the relationship scale (1/5
scales). In the other scales, the HRQoL scores improved
with the exception of the general perception scale, which
maintained the tendency of worsening after treatment.
Different results were found in the group of women
who reported worsening of health between assessments.
The decrease in the HRQoL scores was evident on the
scales that assessed physical well-being and general per-
ceptions (2/5 scale). There were no differences in the re-
lationship scale and the total FACIT-CD score. However,
the treatment satisfaction and emotional well-being
scales improved.
Discussion
To the best of our knowledge, this study is the first to val-
idate a questionnaire (translated into Brazilian Portuguese)
that measures the quality of life of women diagnosed with
cervical intraepithelial neoplasia. The FACIT-CD ques-
tionnaire was developed by Rao et al. [6] in 2010. To date,
no other studies have evaluated the psychometric pro-
perties of this instrument, which means that some com-
parisons are only exploratory.
The first test assessed the reliability of the questionnaire
by analysing the internal consistency using Cronbach’s
alpha coefficient. Results higher than 0.70 indicate that
the items on the scales or domains are homogeneous or
that they measure the same attribute. In this study, the
value on the relationship scale was lower than expected
(0.66). However, other authors support the hypothesis that
Cronbach’s alpha values higher than 0.60 could be accep-
table [31]. Despite this assumption, we believe that a value
of 0.70 would be more desirable, and thus, we considered
that the relationship scale did not achieve adequate in-
ternal consistency. Therefore, these results suggest that
the relationship scale does not measure the same attribute
because it addresses questions about the emotional
Table 2 Cronbach’s alpha coefficients and intraclass correlation coefficients of the FACIT-CD questionnaire
Scale Mean (SD) Median Minimum-maximum Variation Cronbach’s alpha Intraclass correlation coefficient (95% CI)
Physical well-being 23.4 (4.2) 24.0 9–28 0–32 0.70 0.74 (0.62–0.82)
Treatment satisfaction treatment 9.7 (1.9) 9.0 3–12 0–16 0.77 0.50 (0.33–0.64)
General perceptions 18.8 (3.8) 19.0 5–24 0–28 0.76 0.72 (0.51–0.84)
Emotional well-being 30.6 (7.0) 32.0 5–40 0–44 0.79 0.76 (0.65–0.84)
Relationships 8.6 (2.2) 9.0 1–12 0–16 0.66 0.67 (0.54–0.77)
FACIT-CD 91.1 (11.6) 92.0 59–115 0–136 0.73 0.83 (0.75–0.89)
SD Standard deviation, CI Confidence interval
Table 3 Known-group validity of the FACIT-CD questionnaire
Scale Women diagnosed
with CIN
(N = 329)
Women not diagnosed
with CIN (N = 110)
p* Excellent/
Very Good
(N = 90)
Good
(N = 147)
Regular/Poor
(N = 92)
p**
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Physical well-being 23.4 (4.2) 24.8 (3.8) < 0.001 25.2 (8.66) 23.8 (3.9) 21.0 (4.8) < 0.001
Treatment satisfaction 9.7 (1.9) 0.6 (0.6) < 0.001 11.0 (9.63) 9.7 (1.7) 9.2 (1.6) < 0.001
General perceptions 18.8 (3.8) 13.9 (2.6) < 0.001 21.6 (8.71) 18.9 (3.3) 16.6 (4.3) < 0.001
Emotional well-being 30.6 (7.0) 39.8 (0.4) < 0.001 32.6 (9.72) 30.2 (7.0) 30.0 (7.3) 0.048
Relationships 8.6 (2.2) 2.8 (0.6) < 0.001 10.4 (9.62) 8.4 (2.1) 8.0 (2.3) < 0.001
FACIT-CD 91.1 (11.6) 81.7 (4.9) < 0.001 96.4 (10.26) 91.1 (11.0) 85.8 (11.4) < 0.001
CIN cervical intraepithelial neoplasia
*p = Mann-Whitney; p** = Kruskal-Wallis
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support that women receive from their partner and family
combined with questions about their relationships with
friends and support in case of need [8]. We believe that
further studies with other populations are necessary to
compare the results and to determine whether the prob-
lems will be repeated.
The second stage of the study evaluated the reproduci-
bility of the FACIT-CD questionnaire (i.e., the consistency
of the results after repetition of the measurements). Most
of the studies that assessed reproducibility used a period
of 14 ± 5 days [32–34]. Despite this recommendation, the
treatment of intraepithelial lesions is not related to sudden
changes in health status. Therefore, the period between
assessments used in this study was 30 days because this
time frame represented the interval between the col-
poscopy examination and the second medical consult-
ation. The lower limit of the 95% CI of the ICC on the
treatment satisfaction scale was lower than 0.40, indicating
low reproducibility (i.e., the variability in treatment satis-
faction was greater than desired). Some factors reported
Table 4 Factor analysis of the FACIT-CD questionnaire (N = 329)
Scale Item Question Component
1 2 3 4 5
Physical CD1 I have discomfort in my pelvic area (lower part of the stomach) −0.016 −0.025 0.703 0.011 0.011
well-being CD2 I have pain in my pelvic area (lower part of the stomach) −0.028 −0.098 0.701 0.023 0.100
CD3 I have cramping in my pelvic area (lower part of the stomach) 0.027 0.052 0.572 0.003 0.004
Cx1 I am bothered by discharge or bleeding from my vagina 0.213 0.221 0.496 −0.072 −0.177
GP5 I am bothered by side effects of treatment 0.293 0.165 0.063 0.069 −0.180
ES8 I have pain or discomfort with intercourse 0.065 −0.124 0.680 −0.090 0.118
CD4 I have to limit my sexual activity because of the infection 0.122 −0.050 0.665 −0.049 0.014
CD5 I worry about spreading the infection 0.390 0.097 0.403 0.080 −0.133
Treatment GR1 I have confidence in my doctor 0.045 0.216 0.081 0.677 −0.012
satisfaction CD6 I feel I have received the treatment that was right for me −0.001 0.245 0.025 0.764 0.037
CD7 My doctor gave me explanations that I could understand −0.042 0.113 −0.115 0.775 0.201
CD8 My doctor explained the possible benefits of my treatment 0.055 0.060 −0.111 0.768 0.079
General GF1 I am able to work (including at home) 0.091 0.558 −0.012 0.159 0.195
perceptions GF3 I am able to enjoy life −0.129 0.768 0.014 0.083 0.136
HI11 I am hopeful about the future 0.000 0.667 0.072 0.118 0.148
Sp9 I find comfort in my faith or spiritual beliefs 0.013 0.613 0.059 0.100 0.128
GF7 I am content with the quality of my life right now −0.166 0.646 −0.252 0.001 0.116
CD9 I feel that I can manage things that come up around this infection −0.204 0.563 −0.111 0.255 −0.008
CD10 I have accepted that I have this infection −0.359 0.401 0.038 0.260 −0.037
Emotional CD11 I worry that the infection will get worse 0.487 −0.056 0.274 0.022 0.012
well-being CD12 I have hidden this problem so others will not notice 0.700 0.052 −0.050 0.046 −0.251
CD13 I have concerns about my ability to become pregnant 0.354 0.022 0.065 0.108 0.209
BMT18 The cost of my treatment is a burden on me and my family 0.389 −0.078 0.105 −0.046 0.240
CD14 I worry about other people’s attitudes towards me 0.661 −0.223 0.037 0.044 −0.028
CD15 I feel embarrassed about the infection 0.681 −0.163 0.145 −0.015 −0.057
CD16 I tend to blame myself for the infection 0.565 −0.062 0.002 −0.028 −0.070
CD17 I was careful who I told about the infection 0.434 0.214 0.011 0.106 −0.190
CD18 I have had difficulty telling my partner/spouse about the infection 0.529 0.106 −0.052 −0.020 −0.155
CD19 I am frustrated by the infection 0.743 −0.172 0.045 −0.069 0.030
CD20 I am depressed about the infection 0.651 −0.324 0.061 −0.033 0.127
Relationships CD21 I get emotional support from my partner/spouse −0.072 0.147 −0.015 0.032 0.721
CD22 I get emotional support from family members −0.121 0.146 0.043 −0.019 0.722
GS1 I feel close to my friends −0.065 0.252 0.030 0.176 0.372
HI3 I have people to help me if I need it −0.023 0.302 0.018 0.185 0.630
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by the study participants could justify this variability. The
consultations were conducted by different physicians from
the same team, which might lead to dissatisfaction or con-
versely a better evaluation in another consultation. The
impact on the emotional factors of the patient might also
influence this variable (e.g., whether the consultation was
scheduled only to perform follow-up tests such as colpos-
copy or whether it was scheduled to inform the result of a
test that would define a course of action). Emotional fac-
tors in these different instances (consultation for examin-
ation and consultation to receive laboratory test results)
may explain this variability.
The best results were observed in the known-group val-
idity analysis. The comparison of the groups of women
with and without a diagnosis of CIN indicated significant
differences in the scores on all scales. As expected, some
scales showed worsening in the HRQoL scores in women
without the disease. The reason for this difference was ap-
parent in the items that composed the scales. In the scales
that assessed treatment satisfaction and relationships,
women without the disease responded “not at all” on
various items, thereby decreasing the HRQoL scores as
expected because they were not in treatment. The general
perception scale evaluated items such as acceptance of in-
fection and whether women could manage things that
came up around the infection. A decrease in the HRQoL
scores of women without the disease was expected for the
items that composed the scale. These factors contributed
to the decrease in the HRQoL scores in women without
CIN compared with women with CIN based on the
FACIT-CD total score. As expected, the scores of the
other physical and emotional well-being scales were
higher in women without the disease.
In an additional analysis, the test groups were classi-
fied based on the health status rating of each participant,
with a lower score indicating a worse perception of the
HRQoL. In this case, all scales showed significant differ-
ences. This analysis confirmed that the FACIT-CD ques-
tionnaire could differentiate the groups for which
differences were expected.
The structural validity of the questionnaire was tested
by confirmatory factor analysis. The results consistently
Table 5 Correlation coefficients between the FACIT-CD, SF-12, and EORTC QLQ-CX24 questionnaire scales (convergent validity)
Questionnaire Scale FACIT-CD scale
Physical well-being General perceptions Emotional well-being
rs (95% CI) rs (95% CI) rs (95% CI)
SF-12 Physical function 0.20 (0.10–0.31) NA NA
Physical role 0.18 (0.08–0.28) NA NA
Bodily pain 0.16 (0.06–0.27) NA NA
Emotional role NA NA 0.14 (0.04–0.25)
Mental health NA NA 0.38 (0.29–0.47)
General health NA 0.32 (0.22–0.41) NA
Vitality NA 0.28 (0.17–0.37) NA
Social role NA 0.17 (0.06–0.27) NA
Physical component summary 0.17 (0.07–0.27) NA NA
Mental component summary NA NA 0.34 (0.24–0.43)
EORTC QLQ-CX24 Sexual worry −0.53 (−0.61 to −0.45) NA NA
Sexual/vaginal function −0.49 (−0.58 to −0.40) NA NA
rs Spearman correlation coefficient, CI Confidence interval, NA Not available
Table 6 Evaluation of the sensitivity of the FACIT-CD questionnaire
Scale Pre-treatment
(n = 179)
Post-treatment
(n = 179)
Difference between means p* ES SRM
Mean SD Mean SD Mean SD
Physical well-being 23.1 4.3 24.9 4.5 1.7 4.6 < 0.001 0.40 0.37
Treatment satisfaction treatment 9.6 1.8 10.1 1.5 0.5 1.9 < 0.001 0.31 0.29
General perceptions 18.6 3.7 17.2 3.3 −1.4 2.7 < 0.001 −0.37 −0.51
Emotional well-being 30.3 6.8 33.2 5.6 2.9 5.5 < 0.001 0.43 0.52
Relationships 8.5 2.1 8.9 2.2 0.3 2.0 < 0.001 0.17 0.19
FACIT-CD 90.2 11.0 94.5 10.8 4.2 9.6 < 0.001 0.38 0.44
SD Standard deviation; p* = Wilcoxon; ES Effect Size, SRM Standardized response mean
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confirmed the structure of the original questionnaire,
which contained five factors. The only exception was in
the fifth item of the physical well-being scale, which
assessed the side effects of treatment. This item showed
higher factor loading in the emotional well-being scale.
The follow-up and treatment of women diagnosed with
CIN have a greater emotional impact than physical impact
[8]. Women who seek medical care after the diagnosis of
changes in the Papanicolaou test rarely complain of phys-
ical changes but often complain of psychological changes
[10–12]. This finding suggests that item GP5 ("I am both-
ered by side effects of treatment") is better allocated in the
emotional well-being scale. On the other hand, confirma-
tory factor analysis is very sensitive to sample size, and its
consistency requires a relatively large number of cases
[35]. Therefore, an increase in the sample size may help
confirm the new positioning of the variable in the model.
Regarding the convergent and divergent validities of
the FACIT-CD questionnaire, we expected to find a cor-
relation between the SF-12 and FACIT-CD questionnaire
scales. However, no correlation was found, and the
values were lower than 0.40. This result may have oc-
curred because the SF-12 is a generic questionnaire that
does not specifically address the questions explored in
the FACIT-CD; therefore, the purposes of the evalua-
tions were distinct. Another study that used a generic
and a specific questionnaire reported the same problem
when correlating the questionnaires [33]. This analysis
was also conducted using the EORTC QLQ-CX24 ques-
tionnaire, which was developed to assess the HRQoL of
women with cervical cancer and could easily calculate
the scores of the scales and some items separately.
Therefore, for this study, only the scales that assessed
sexuality were used. The results of the correlation be-
tween the scales of the FACIT-CD and EORTC QLQ-
CX24 questionnaires were satisfactory. In this case, it
was possible to confirm the correlation of the FACIT-
CD questionnaire with other dimensions for which a
correlation was already expected.
Some of the women who participated in the first stage
of the study and were treated surgically (LEEP) were
interviewed again 6 months after surgery. In this ana-
lysis, improvements in the scale scores were expected
after treatment using the SRM and relative efficiency
(ES). The goal was achieved for all scales except for the
general perception scale. The scale scores improved after
surgery, and the sensitivity was considered low to mod-
erate. The general perception scale indicated deterior-
ation in the overall score; however, it was not possible to
identify which items worsened. In the present study, we
used the classical test theory (CTT), which tests the val-
idity of an instrument (i.e., the ability to measure what it
proposed to measure), for the psychometric analysis of
the FACIT-CD questionnaire [36]. However, future studies
should conduct other analyses using the item response
theory (IRT) [37], which investigates items separately. [37]
Table 7 Analysis of responsiveness of the FACIT-CD questionnaire
Scale Health status n Pre-treatment Post-treatment Difference between means ES SRM p*
Mean SD Mean SD Mean SD
Physical well-being No change 73 23.2 4.4 24.7 5.0 1.5 5.2 0.34 0.29 0.008
Improvement 83 22.9 4.3 25.5 3.2 2.5 4.0 0.58 0.63 < 0.001
Worsening 23 23.4 4.6 23.1 6.0 −0.3 4.5 −0.07 −0.07 0.87
Treatment satisfaction No change 73 9.7 1.8 10.0 1.5 0.3 2.0 0.18 0.16 0.009
Improvement 83 9.5 1.8 10.2 1.5 0.7 1.9 0.43 0.38 < 0.001
Worsening 23 9.7 1.9 10.2 1.8 0.5 1.5 0.27 0.35 0.028
General perceptions No change 73 18.5 4.0 16.6 3.8 −1.9 3.0 −0.48 −0.65 < 0.001
Improvement 83 18.5 3.7 17.4 2.8 −1.0 2.6 −0.29 −0.41 0.001
Worsening 23 19.1 2.7 18.3 2.5 −0.8 2.2 −0.29 −0.36 0.124
Emotional well-being No change 73 30.3 6.6 33.3 5.2 3.0 5.5 0.45 0.54 < 0.001
Improvement 83 29.8 7.3 32.9 6.2 3.1 5.7 0.42 0.54 < 0.001
Worsening 23 32.0 5.3 34.0 4.7 1.9 5.3 0.36 0.36 0.038
Relationships No change 73 8.6 2.1 8.8 2.2 0.2 1.9 0.009 0.10 0.021
Improvement 83 8.4 2.2 9.0 2.0 0.6 2.0 0.27 0.30 0.003
Worsening 23 9.0 2.1 9.1 2.9 0.1 2.1 0.06 0.06 0.284
FACIT-CD (total) No change 73 90.4 11.2 93.6 11.7 3.1 10.7 0.27 0.29 0.003
Improvement 83 89.2 10.9 95.2 9.9 5.9 8.4 0.55 0.71 < 0.001
Worsening 23 93.4 10.3 94.9 11.3 1.4 9.7 0.14 0.15 0.429
SD Standard deviation, p* = Wilcoxon; ES Effect size, SRM Standardized response mean
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Furthermore, the responsiveness of the FACIT-CD ques-
tionnaire was evaluated using the same group in which
sensitivity was measured before and after treatment. Other
studies have used a methodology similar to ours to evalu-
ate responsiveness [38–40]. However, in this case, the
women were divided based on their self-reported health
status. After treatment, the participants answered the
FACIT-CD questionnaire and the first question of the SF-
12 questionnaire (on health rating). Finally, the answers
provided to this question before and after treatment were
compared to allow the classification of the groups as
improved, worsened, or no change in health status. In the
group of 83 women who exhibited improved health, we
noticed an increase in the scores of the scales, reflecting
an improvement in HRQoL. The total score of the
FACIT-CD indicated moderate responsiveness. Respon-
siveness was low in the groups of women who reported
health worsening or had no changes in health status. The
HRQoL scores improved even among women who re-
ported not having good health. We believe that other
health problems may have interfered with the responses
and that there is no direct correlation between health
worsening and the worsening of signs and symptoms
resulting from CIN.
Conclusions
Our results are encouraging and indicate that the FACIT-
CD questionnaire is a promising tool for the analysis of
HRQoL in women with CIN. Internal consistency and re-
producibility were satisfactory. Regarding structural valid-
ity, only one item on the physical well-being scale was
not kept in the original domain. The questionnaire was
able to discriminate the groups according to disease
status and self-rating of health. Sensitivity was low for
the relationship scale, but moderate for the other scales.
Responsiveness varied between the groups that denom-
inate the self-perception of health as no change, im-
provement or worsening.
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